.jpeg)
2026-03-24 04:27:54
Pegcetacoplan is a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) treatment. This article details injection reactions, infection risks and monitoring points to help patients use medication safely.
2026-03-20 03:20:58
Pegcetacoplan is a PEGylated complement C3 inhibitor used for treating adult paroxysmal nocturnal hemoglobinuria, providing comprehensive control of complement-mediated hemolytic reactions.
2026-03-19 04:04:05
Eltrombopag is a novel oral TPO receptor agonist that stimulates bone marrow megakaryocytes to promote platelet production, providing non-immunosuppressive treatment options for patients with immune thrombocytopenia and aplastic anemia.
2026-03-17 06:58:36
MDS targeted drugs are not chemotherapy; they are precision treatments targeting specific molecular markers. This article details the mechanistic differences, the critical role of genetic testing, side effect comparisons, and personalized strategies for children, the elderly, and patients with comorbidities.
2026-03-13 07:08:13
Enasidenib is the first approved oral IDH2 inhibitor, brand name Idhifa, designed for patients with relapsed or refractory acute myeloid leukemia carrying IDH2 mutations. This article details mechanism of action, indications, dosage and adverse reaction management.
2026-03-13 05:38:15
Anagrelide is an oral platelet production inhibitor for treating essential thrombocythemia. This article covers indications, recommended dosage, administration methods, efficacy monitoring and common side effects for safe medication use.
2026-03-06 05:19:40
Compare Romiplostim (subcutaneous) and Eltrombopag (oral) for ITP, highlighting administration, onset time, side effects, and clinical decision factors to optimize personalized therapy.
2026-03-06 04:55:21
Decoding asciminib (Asciminib)'s targeting of the ABL myristoyl pocket, its breakthrough role in treating CML resistance, pharmacokinetics, and clinical advantages for informed patient decisions.
2026-03-04 07:32:53
Explore whether Ixazomib (Ninlaro) requires long-term use for Multiple Myeloma. Analyze its critical role in induction and maintenance therapy, the impact of long-term adherence on extending progression-free survival, and expert advice on side effect management and personalized discontinuation strategies.
2026-02-28 03:31:21
Isatuximab (Sarclisa) is a CD38-targeting monoclonal antibody approved for relapsed/refractory and newly diagnosed Multiple Myeloma. Its mechanism involves apoptosis induction, ADCC immune killing, and enzymatic inhibition. Clinical data confirms extended Progression-Free Survival (PFS) and improved MRD negativity with combination regimens. This guide covers IV infusion protocols, Infusion-Related Reaction (IRR) management, and patient quality of life insights for optimized treatment decisions.
2026-02-09 04:16:06
As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.
